3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
45
Stomach Neoplasms
20
Pancreatic Neoplasms
20
Rectal Neoplasms
16
Adenocarcinoma Of Esophagus
14
Esophageal Neoplasms
13
Colonic Neoplasms
12
Neoplasms
11
Neoplasm Metastasis
11
Carcinoma, Non-Small-Cell Lung
11
Urinary Bladder Neoplasms
8
Squamous Cell Carcinoma of Head and Neck
8
Esophageal Squamous Cell Carcinoma
7
Adenocarcinoma
7
Ovarian Neoplasms
5
Cholangiocarcinoma
5
Parkinson Disease 4, Autosomal Dominant Lewy Body
4
Lung Neoplasms
4
Gastrointestinal Neoplasms
4
Endometrial Neoplasms
4
Carcinoma
4
Head and Neck Neoplasms
3
Carcinoma, Hepatocellular
3
Breast Neoplasms
3
Biliary Tract Neoplasms
3
Advanced Solid Tumors
3
Uterine Cervical Neoplasms
2
Triple Negative Breast Neoplasms
2
Oropharyngeal Neoplasms
2
Melanoma
2
Interventions
Nivolumab
3
tivozanib
1
regorafenib
1
neratinib
1
lutetium Lu 177 dotatate
1
encorafenib
1
durvalumab
1
capivasertib
1
Valproic Acid
1
Thioctic Acid
1
Oxaliplatin
1
Multiparametric Magnetic Resonance Imaging
1
Leucovorin
1
Lenalidomide
1
Gemcitabine
1
Fulvestrant
1
Folfox protocol
1
Fluorouracil
1
Cisplatin
1
Cetuximab
1
Bortezomib
1
Blood Specimen Collection
1
Biopsy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Disease Progression
×
Fluorouracil
×
90 days
×
Clear all
NCT05712356
2026-05-26
BOLSTER
Lisata Therapeutics, Inc.
Phase 2
Terminated
66 enrolled
12 charts